Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ATM is a large serine/threonine protein kinase that plays a central role in the cellular response to DNA double-strand breaks (DSBs) and other forms of cellular stress. It is best known as the product of the gene mutated in ataxia-telangiectasia, a rare autosomal recessive disorder. ATM acts as a master regulator for signal transduction following DNA damage, phosphorylating key proteins and initiating cell cycle checkpoints. Loss-of-function mutations in ATM cause ataxia-telangiectasia. Targeted inhibition of ATM has been explored as a strategy for radiosensitizing tumors during cancer therapy.
Inhibition of ATM kinase activity, blocking downstream signaling pathways involved in DNA damage repair and cell cycle arrest.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ataxia Telangiectasia Mutated Protein (ATM).